Corrected: Rite Aid forecast worse than expected; shares down
(Corrects days of trading in last paragraph)
NEW YORK - Rite Aid Corp
The results marked the No. 3 U.S. drugstore chain's 11th straight quarterly loss and were hurt by a 1.7 percent drop in the number of prescriptions filled at stores open at least a year. Prescription sales made up two-thirds of total drugstore sales.
It was a difficult quarter with continued weak consumer demand, a weaker cough, cold and flu season than last year, and continued pressure on pharmacy reimbursement, Chief Executive Mary Sammons said in a statement.
Rite Aid posted a loss of $208.4 million, or 24 cents per shares, in the fourth quarter ended on February 27 from a loss of $2.29 billion, or $2.67 per share, a year earlier.
Analysts on average had forecast a loss of 19 cents a share, according to Thomson Reuters I/B/E/S.
Sales fell 3.6 percent to $6.46 billion.
Sales at stores open at least a year fell 2.4 percent, the company said in early March. Same-store sales of general merchandise sold dropped 2.6 percent while pharmacy same-store sales fell 2.4 percent.
The new fiscal year showed some moderation in that decline, with same-store sales falling by 0.1 percent in March. Rite Aid forecast same-store sales would range from a decline of 1 percent to an increase of 1 percent in its fiscal 2011.
The drugstore chain said it expects the economy to remain weak with high unemployment and forecast a fiscal 2011 loss per share of between 41 cents and 65 cents, while analysts expect a loss of 36 cents.
Rite Aid has had a hard time boosting sales at the Brooks and Eckerd stores it bought from Canada's Jean Coutu
in 2007. The acquisition, which saddled Rite Aid with debt, came just before the recession hit and shoppers cut back.
Rite Aid has refinanced debt, trimmed expenses and taken other steps to improve its position, but has yet to show a major turnaround as shoppers cut back on discretionary purchases.
Shares were down 19 cents at $1.50 before the bell on Wednesday. They closed at $1.69 on Tuesday on the New York Stock Exchange.
(Reporting by Phil Wahba; additional reporting by Jessica Wohl; Editing by Lisa Von Ahn, Dave Zimmerman)
© Copyright Thomson Reuters 2024. All rights reserved.